Netherlands
· Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 636.74 million. The enterprise value is 648.92 million.
| Market Cap | 636.74M |
| Enterprise Value | 648.92M |
Important Dates
The next estimated earnings date is Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 683.93 million shares outstanding. The number of shares has increased by 2.22% in one year.
| Current Share Class | 683.93M |
| Shares Outstanding | 683.93M |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | -9.59% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 7.35% |
| Float | 669.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.15 |
| PB Ratio | 3.20 |
| P/TBV Ratio | 9.16 |
| P/FCF Ratio | 135.16 |
| P/OCF Ratio | 113.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.21, with an EV/FCF ratio of 137.74.
| EV / Earnings | -49.70 |
| EV / Sales | 2.19 |
| EV / EBITDA | 37.21 |
| EV / EBIT | 58.45 |
| EV / FCF | 137.74 |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.76 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 5.86 |
| Debt / FCF | 23.40 |
| Interest Coverage | 1.10 |
Financial Efficiency
Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 2.38%.
| Return on Equity (ROE) | -6.78% |
| Return on Assets (ROA) | 1.99% |
| Return on Invested Capital (ROIC) | 2.38% |
| Return on Capital Employed (ROCE) | 4.14% |
| Revenue Per Employee | 734,453 |
| Profits Per Employee | -32,318 |
| Employee Count | 404 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 0.61 |
Taxes
In the past 12 months, Pharming Group has paid 9.83 million in taxes.
| Income Tax | 9.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.17% in the last 52 weeks. The beta is 0.54, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +23.17% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 48.39 |
| Average Volume (20 Days) | 11,057,874 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 296.72 million and -13.06 million in losses. Loss per share was -0.02.
| Revenue | 296.72M |
| Gross Profit | 264.03M |
| Operating Income | 12.47M |
| Pretax Income | -3.38M |
| Net Income | -13.06M |
| EBITDA | 15.68M |
| EBIT | 12.47M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 99.25 million in cash and 110.23 million in debt, giving a net cash position of -10.98 million or -0.02 per share.
| Cash & Cash Equivalents | 99.25M |
| Total Debt | 110.23M |
| Net Cash | -10.98M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | 199.19M |
| Book Value Per Share | 0.30 |
| Working Capital | 126.35M |
Cash Flow
In the last 12 months, operating cash flow was 5.63 million and capital expenditures -917,798, giving a free cash flow of 4.71 million.
| Operating Cash Flow | 5.63M |
| Capital Expenditures | -917,798 |
| Free Cash Flow | 4.71M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 88.98%, with operating and profit margins of 4.20% and -4.40%.
| Gross Margin | 88.98% |
| Operating Margin | 4.20% |
| Pretax Margin | -1.14% |
| Profit Margin | -4.40% |
| EBITDA Margin | 5.29% |
| EBIT Margin | 4.20% |
| FCF Margin | 1.59% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.22% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.05% |
| FCF Yield | 0.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.19 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.19 |
| Piotroski F-Score | 6 |